

## **NOHLA THERAPEUTICS CLOSES OVERSUBSCRIBED US\$21M PRIVATE FINANCING ROUND AND STRENGTHENS BOARD WITH NEW APPOINTMENT**

Nohla Therapeutics Inc. (Nohla), a leading developer of cellular therapies for hematological disorders and immunological diseases, announced today that it has closed an over-subscribed first capital raising round. Nohla closed the round with USD \$21m raised from several institutional investors.

In conjunction with this capital raising, Nohla announced a new leadership appointment today. Mr. Lawrence Gozlan will join the company's Board of Directors. Mr Gozlan is the Chief Investment Officer and Founder of Scientia Capital, a specialized global investment fund focused exclusively in life sciences. With 15 years of experience in investing and banking, Mr Gozlan has expertise in all areas of investment management and deep roots in the scientific and biotech communities.

Prior to Scientia Mr Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC ("the Queensland Investment Corporation"), an investment fund with over AU\$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking, and gained corporate finance experience advising life science companies at Deloitte.

Mr Gozlan currently serves as a Director on the Board of Prana Biotechnology (NASDAQ: PRAN). He holds a Bachelor of Science with Honours in immunology from the University of Melbourne.

"I am delighted to join the Board of Nohla Therapeutics", said Mr. Gozlan, "The cellular therapy platform developed by Dr. Colleen Delaney and Dr. Irwin Bernstein at the Fred Hutch provides an unmatched clinical and commercial advantage over all other approaches currently being developed in the fields of stem cell transplant and immuno-oncology. The clinical data generated thus far is exceptional and the technology platform has the potential to be the cornerstone of next generation cellular therapies."

Mr. Michael Sistenich, Chief Business Officer for Nohla stated, "We are delighted that Lawrence has agreed to lend his experience and expertise to Nohla. His leadership in the biotech sector will be invaluable to Nohla in the years ahead as we aim to transform the treatment paradigm of stem cell transplants and build a broad pipeline of innovative allogeneic immunotherapies."

### **About Nohla Therapeutics**

Nohla Therapeutics Inc. (Nohla) is a clinical stage company developing world leading cellular therapies. Leveraging technology developed over the past two decades at the Fred Hutchinson Cancer Research Center, Nohla's lead product is an ex vivo expanded hematopoietic stem and progenitor cell therapy derived from umbilical cord blood that is used clinically without any requirement for HLA matching. The product is truly 'off-the-shelf' and is available to all potential patients on demand at the time of treatment. Hematopoietic stem cell transplant remains the only proven cure for many hematologic malignancies, and multiple clinical trials infusing Nohla's lead product have demonstrated reduced time to neutrophil and platelet engraftment, decreased rates of severe acute graft versus host disease and decreased transplant related mortality, and best-in-class improvements in overall survival. This expanded hematopoietic cell therapy has also been safely used in patients following high dose chemotherapy to prevent life threatening complications that result from prolonged neutropenia. Thus, in addition to treating many thousands of cancer patients each year who undergo high dose chemotherapy regimens, this product could be used to prevent and treat infectious complications in patients with neutropenia, regardless of cause.

ENDS

#### **General enquiries**

Benjamin Bergo  
CEO  
Nohla Therapeutics Inc.  
P: + 1 206 310 5560  
E: [benb@nohlatherapeutics.com](mailto:benb@nohlatherapeutics.com)

#### **Investors**

Michael Sistenich  
Chief Business Officer  
Nohla Therapeutics Inc.  
P: +61 (0)413 087 194  
E: [michaels@nohlatherapeutics.com](mailto:michaels@nohlatherapeutics.com)

#### **Media**

Ben Walsh  
Buchan Consulting  
P: +61 (0)468 422 865  
E: [bwalsh@buchanwe.com.au](mailto:bwalsh@buchanwe.com.au)